AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia

Group 1 - AbbVie, Inc. announced the acquisition of Cerevel Therapeutics for $8.7 billion, enhancing its neuroscience pipeline with promising candidates like Emraclidine and Tavapadon [1] - The acquisition was completed in December 2023, indicating AbbVie's strategic focus on expanding its capabilities in neuroscience [1] Group 2 - The company has a strong background in life sciences, with over 20 years of experience in research and development of novel Cell & Gene Therapies [1] - AbbVie aims to leverage its expertise in life sciences to assess the potential of new treatments and their ability to drive shareholder returns [1]